| Company Name: | Accentia Pharmaceuticals, Inc. | | Ticker Symbol: | ABPI | | | WWW Address: | www.accentia.net | | CEO: | Dr. Francis E. O'Donnell, Jr., M.D. | | No. of Employees: | 140 | | Common Issue Type: | CS | | Business Description: | A biopharmaceutical company focused on the development and commercialization of late-stage, targeted therapeutic clinical products.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 0.23 |  0.0 | - | - | 0 | 0.29 | 0.21 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 11.6 | 50.3 | 2.33 | -2.21 | 0.00 | 0.0 | 0.0 | 3.39 - 0.21 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 0.23 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 11.6 | mil |
| Latest Shares Outstanding | 50.3 | mil |
| Earnings pS (EPS) | -2.21 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 130,595 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 44.3 | mil |
| Float as % of Shares Outstanding | 88.1 | % |
| Foreign Sales | 4 | mil |
| Domestic Sales | 14 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 184.20 | % |
| Research & Devlopment (R&D) as % of Revenue | 81.90 | % |
| Gross Profit Margin | 72.8 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.5 | % |
| Return on Assets (ROA) | -186.0 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | 74.0 | % |
| Current Ratio | 0.1 | |
| Leverage Ratio (Assets/Equity) | 0.0 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | -1.66 | $ |
| Cash pS | 0.09 | $ |
| Book-Value pS | 0.00 | $ |
| Tangible Book-Value pS | -2.10 | $ |
| Cash Flow pS | -1.10 | $ |
| Free Cash Flow pS | -0.53 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 0.00 | |
| Price/Tangible Book Ratio | -0.11 | |
| Price/Cash Flow | -0.2 | |
| Price/Free Cash Flow | -0.4 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -14.8 | 85 | 2,910 | 8,779 |
| 4 Weeks | 0.46 | 0.21 | 0.27 | -14.8 | 79 | 2,523 | 40,364 |
| 13 Weeks | 0.99 | 0.21 | 0.94 | -75.5 | 33 | 2,571 | 154,233 |
| 26 Weeks | 1.94 | 0.21 | 1.02 | -77.5 | 32 | 3,088 | 379,793 |
| 52 Weeks | 3.39 | 0.21 | 2.14 | -89.3 | 16 | 3,022 | 746,450 |
| YTD | 3.31 | 0.21 | - | -93.0 | 11 | 3,329 | 709,084 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 0.29 | 0.32 | 0.50 | 0.84 | 1.22 | 2.33 | 2.48 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.00 | 0.0 | -12.39 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 0.00 | NA | 45.91 |
| R&D | 0.00 | NA | 18.22 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -19.3 | -21.3 | -27.0 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.89 | 0.46 | -0.65 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | -160.62 |
| Current Ratio | 0.2 |
| Quick Ratio (Acid Test) | 0.1 |
| Liquidity Ratio (Cash) | 0.06 |
| Receivables Turnover | 3.9 |
| Average Collection Period | 92 |
| Working Capital/Equity | 81.5 |
| Working Capital pS | -1.34 |
| Cash-Flow pS | -1.88 |
| Free Cash-Flow pS | -1.11 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | -10.21 |
| Financial Leverage Ratio (Assets/Equity) | 0.0 |
| Debt Ratio | 297.0 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | -70.8 |
| LT Debt/Total Liabilities | 20.4 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | -58.25 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 28.67 |
| Tobin's Q Ratio | 0.35 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -2.90 |
| Enterprise Value (EV)/Free Cash Flow | -0.59 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | -0.11 |
| Price/Book Ratio - LTM | 0.00 |
| Price/Cash Flow Ratio | -0.2 |
| Price/Free Cash Flow Ratio - LTM | -0.4 |
| Price/Sales Ratio | 0.74 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.51 |
| Current Liabilities pS | 1.67 |
| Tangible Book Value pS - LTM | -2.10 |
| Book Value pS - LTM | 0.00 |
| Capital Invested pS | -0.90 |
| Cash pS - LTM | 0.09 |
| Cash Flow pS - LTM | -1.10 |
| Free Cash Flow pS - LTM | -0.53 |
| Earnings pS (EPS) | -2.21 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -239.57 |
| Free Cash Flow Margin 5YEAR AVG | -130.38 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | -0.28 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | -0.41 |
| Return on Capital Invested (ROCI) | 168.7 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 268.6 |
| Assets Productivity | 0.40 |
| Return on Assets (ROA) | -230.0 |
| Return on Assets (ROA) - 5YEAR AVRG. | -112.1 |
| Gross Profit Margin | 72.8 |
| Gross Profit Margin - 5YEAR AVRG. | 76.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.2 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 212 |
| Revenue per Employee | 130,595 |
| Net Income per Employee | -542,935 |
| Average Collection Period | 107 |
| Receivables Turnover | 3.9 |
| Day's Inventory Turnover Ratio | 105 |
| Inventory Turnover | 3.4 |
| Inventory/Sales | 8.2 |
| Accounts Payble/Sales | 86.26 |
| Assets/Revenue | 2.50 |
| Net Working Capital Turnover | -0.34 |
| Fixed Assets Turnover | 0.92 |
| Total Assets Turnover | 0.4 |
| Revenue per $ Cash | 11.26 |
| Revenue per $ Plant | 10.38 |
| Revenue per $ Common Equity | -0.28 |
| Revenue per $ Capital Invested | -0.41 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 162.5 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 143.8 |
| Research & Devlopment (R&D) as % of Revenue | 108.7 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 108.7 |
|
|  
|
| |
 |  |